Oxycodone/naltrexone - Pfizer
Alternative Names: ALO-02; Naltrexone/oxycodone - Pfizer; Oxycodone-naltrexone core (King); TROXYCAERLatest Information Update: 05 Nov 2023
At a glance
- Originator Pfizer
- Class Analgesics; Cyclopropanes; Drug withdrawal therapies; Ethers; Ketones; Morphinans; Morphine derivatives; Opioid analgesics; Small molecules
- Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists; Opioid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Pain(In volunteers) in USA (IV, Injection)
- 18 Oct 2016 Launched for Pain (Abuse-resistant) in USA (PO) before October 2017 (Martindale/Pfizer website, November 2017)
- 19 Aug 2016 Registered for Pain (Abuse-resistant) in USA (PO)